ELREXFIO 76 MG / 1.9 ML
ELRANATAMAB : 76 MG / 1.9 ML · DIN 02543567 · PFIZER CANADA ULC
Health Canada status: MARKETED
What is ELREXFIO?
ELREXFIO 76 MG / 1.9 ML contains ELRANATAMAB : 76 MG / 1.9 ML. It is listed in the Health Canada Drug Product Database under DIN 02543567, held by PFIZER CANADA ULC, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 23-Jan-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ELREXFIO used for?
Elrexfio (elranatamab injection) is a B-cell maturation antigen (BCMA)-directed and CD3-directed bispecific antibody indicated as monotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02543567 |
|---|---|
| Brand name | ELREXFIO |
| Generic / active ingredient | ELRANATAMAB : 76 MG / 1.9 ML |
| Manufacturer | PFIZER CANADA ULC |
| Strength | 76 MG / 1.9 ML |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Prescription |
| ATC code | L01FX32 ELRANATAMAB |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 23-Jan-2024 |
How is it stored and handled?
null
How is it supplied?
null
What can be used instead?
Other Canadian products sharing ATC code L01FX32 ELRANATAMAB. 2 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ELREXFIO | 44 MG / 1.1 ML | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02543559 |
Who else supplies ELRANATAMAB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ELRANATAMAB appears in 16 registered pack listings across 7 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.